Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2009

NicOx Reacquires Nitric Oxide-Donating Ophthalmology Compounds from Pfizer

  • NicOx reacquired full development and commercialization rights to clinical-stage glaucoma candidate PF-03187207 from Pfizer along with the rights to a number of other research-stage nitric oxide-donating ophthalmology compounds.

    PF-03187207 has completed two Phase II trials in patients with primary open angle glaucoma and ocular hypertension. NicOx says that it will now evaluate its opportunities for moving PF- 03187207 into Phase III trials, possibly in partnership with a third party.

    As part of the deal, NicOx will get the full current data-package and development information for PF-03187202. The company will also be able to access certain proprietary data relating to Pfizer’s Xalatan®, which is marketed for reducing intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension. NicOx says that the Xalatan data could be important for the future development and regulatory filing of PF-03187207. Phase II trials carried out by Pfizer suggested PF-03187207 may more sustainably lower IOP than Xalatan.

    “This agreement demonstrates our ongoing commitment to out-license and to allow partner companies to reacquire R&D programs that are no longer core to our strategy but could become important medicines for patients and physicians,” comments David K Rosen, head of out-licensing at Pfizer.

    Prizer recorded revenues of over $1.7 billion in 2008 from sales of Xalatan and Xalacom, up 9% from 2007. Xalacom is a fixed combination of Xalatan and the beta blocker timolol.


Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »